Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.
about
Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Safety and reactogenicity of primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Vietnamese infants: a randomised, controlled trial.The 7-valent pneumococcal conjugate vaccine elicits cross-functional opsonophagocytic killing responses to Streptococcus pneumoniae serotype 6D in children.Genomics Reveals the Worldwide Distribution of Multidrug-Resistant Serotype 6E PneumococciDirect Comparison of Immunogenicity Induced by 10- or 13-Valent Pneumococcal Conjugate Vaccine around the 11-Month Booster in Dutch Infants.Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.Impact of IgM Antibodies on Cross-Protection against Pneumococcal Serogroups 6 and 19 after Immunization with 7-Valent Pneumococcal Conjugate Vaccine in Children.Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children.Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.Dosing schedules for pneumococcal conjugate vaccine: considerations for policy makersThe differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.Glycoconjugate vaccines.10-Valent pneumococcal non-typeable haemophilus influenzae protein D-conjugate vaccine: a review in infants and children.Safety and tolerability of pneumococcal vaccines in children.Immunization with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) according to different schedules in infants in South Africa: a phase III trial.Glycerophosphorylcholine regulates Haemophilus influenzae glpQ gene expression.Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.Evaluation of different infant vaccination schedules incorporating pneumococcal vaccination (The Vietnam Pneumococcal Project): protocol of a randomised controlled trial.
P2860
Q33723540-AA4A3FB4-E62D-4BEB-A91A-9771EB0BBB6DQ34082225-C04710E8-5EB3-4C27-BF99-9693B510CF94Q34170021-C716D535-1E3E-40CD-BBCB-A98290EB205AQ34595848-F9472EFD-11EB-4631-8F57-64DE3AF0EEE3Q35013379-8A6C229C-E74B-40E1-B7AB-07EB1C0F7A7AQ35757571-F30D8A30-98E8-4324-9D63-12C50F7720CCQ35867061-4FE1C310-1B9B-46FD-BD2A-362FD0284C08Q36256464-24BBAB9A-1BEB-45CD-A1F7-6854EA0DA191Q36859901-AA5A5058-7419-43A5-B96C-2BC5DC69C5A5Q37384762-DFCE093A-90DC-4617-A8DE-8E809491C73CQ37445704-12B19DAE-94D4-42DD-863F-145B2994AE16Q37613613-85332B70-49F8-4295-A402-0BDD1E7F884CQ37613616-238BE9EA-B5D5-4D78-9427-2E430DA1ED73Q37621061-3C772525-E11D-476C-AEA5-5B3402E37179Q37951530-74745209-AFA5-473F-A09E-7A485C62B4E5Q38044755-A0B8D738-ACF2-4B2A-BAE8-590EA906D63EQ38246355-072C45E0-F428-4C91-B310-8AE0B9A43BCEQ38753554-66895F53-83E7-4A00-B170-D955222C6E1EQ38829068-68395260-6EB5-463C-82B3-9C3EB6538F34Q41119997-5A038710-CFF8-43A5-BAE2-0B8795EA6881Q54416744-1478DC80-164B-4070-933C-C8748796C023Q55313306-49A549F0-FC35-4696-9A51-949478563D7B
P2860
Immunogenicity of a 2-dose priming and booster vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Immunogenicity of a 2-dose pri ...... e protein D conjugate vaccine.
@en
Immunogenicity of a 2-dose pri ...... e protein D conjugate vaccine.
@nl
type
label
Immunogenicity of a 2-dose pri ...... e protein D conjugate vaccine.
@en
Immunogenicity of a 2-dose pri ...... e protein D conjugate vaccine.
@nl
prefLabel
Immunogenicity of a 2-dose pri ...... e protein D conjugate vaccine.
@en
Immunogenicity of a 2-dose pri ...... e protein D conjugate vaccine.
@nl
P2093
P1476
Immunogenicity of a 2-dose pri ...... ae protein D conjugate vaccine
@en
P2093
Birthe Hogh
Dorota Borys
Helena Skerlikova
Lode Schuerman
Marianne Riise Bergsaker
Patricia Lommel
P304
P356
10.1097/INF.0B013E3181B48CA3
P577
2009-10-01T00:00:00Z